Development and validation of a methotrexate adherence assay

BACKGROUND: The first-line therapy for rheumatoid arthritis (RA) is weekly oral methotrexate (MTX) at low dosages (7.5–25 mg/week). However, ~40% of patients are non-adherent which may explain why some do not respond and need to start more expensive biological therapies. To monitor adherence more ac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Bluett, James, Riba-Garcia, Isabel, Verstappen, Suzanne M M, Wendling, Thierry, Ogungbenro, Kayode, Unwin, Richard D, Barton, Anne
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788879/
https://ncbi.nlm.nih.gov/pubmed/31167761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-215446
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados